<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433485</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000522464</org_study_id>
    <secondary_id>YALE-HIC-26866</secondary_id>
    <nct_id>NCT00433485</nct_id>
  </id_info>
  <brief_title>Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants</brief_title>
  <official_title>In Vivo and In Vitro Pharmacology of Sirolimus in Subjects With Basal Cell Nevus Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and tissue from patients with basal cell nevus syndrome&#xD;
      and from healthy participants in the laboratory may help doctors learn more about changes&#xD;
      that may occur in DNA and identify biomarkers related to basal cell nevus syndrome.&#xD;
      Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming&#xD;
      back. The use of sirolimus may keep basal cell skin cancer from forming in patients with&#xD;
      basal cell nevus syndrome.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying topical sirolimus in patients with basal cell nevus&#xD;
      syndrome and in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare messenger RNA and protein expression patterns in patients with basal cell nevus&#xD;
           syndrome (BCNS) vs in cultured cells of healthy participants (control) before treatment&#xD;
           to identify a set of genes that are differentially expressed in BCNS.&#xD;
&#xD;
        -  Assess the effects of topical sirolimus on gene expression (genes identified in the&#xD;
           primary objective) in vivo using keratinocytes, fibroblasts, and lymphocytes from&#xD;
           patients with BCNS and from healthy participants (controls) by targeted expression&#xD;
           methods.&#xD;
&#xD;
      OUTLINE: Patients and healthy participants receive topical sirolimus ointment twice daily for&#xD;
      12 weeks.&#xD;
&#xD;
      Blood and skin biopsies are obtained at baseline and at week 12 for gene and protein&#xD;
      expression studies. Alterations in RNA are measured by microarray analysis. Alterations in&#xD;
      protein expression are measured by 2-dimensional gel electrophoresis and matrix-assisted&#xD;
      laser desorption ionization time-of-flight mass spectrometry.&#xD;
&#xD;
      After completion of study therapy, patients and healthy participants are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 16 patients and healthy participants will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alterations in RNA as measured by microarray analysis</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Alterations in protein expression as measured by 2-dimensional gel electrophoresis and matrix-assisted laser desorption ionization time-of-flight mass spectroscopy</measure>
  </primary_outcome>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Neoplastic Syndrome</condition>
  <condition>Non-melanomatous Skin Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>comparative genomic hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Patient&#xD;
&#xD;
               -  Confirmed diagnosis of basal cell nevus syndrome (BCNS)&#xD;
&#xD;
               -  Known patched (PTCH) gene mutation&#xD;
&#xD;
                    -  Must have full sequence of coding exons with intron/exon junctions in the&#xD;
                       PTCH gene OR prior genetic testing confirming PTCH mutation by the Yale&#xD;
                       University DNA Diagnostics Laboratory&#xD;
&#xD;
          -  Age- and sex-matched healthy participant (control)&#xD;
&#xD;
               -  Unaffected relative of patient OR normal healthy volunteer with no family history&#xD;
                  of BCNS or features of BCNS&#xD;
&#xD;
                    -  No unrelated healthy participant meeting any of the following clinical&#xD;
                       criteria for BCNS:&#xD;
&#xD;
                         -  Lamellar calcification of the falx cerebri&#xD;
&#xD;
                         -  Prior odontogenic keratocyst or any jaw cyst for which a&#xD;
                            histopathologic diagnosis cannot be ascertained&#xD;
&#xD;
                         -  Palmar or plantar pits typical of BCNS&#xD;
&#xD;
                         -  More than 3 basal cell carcinomas (BCC) in a lifetime or 1 BCC under&#xD;
                            the age of 30&#xD;
&#xD;
                         -  History of medulloblastoma&#xD;
&#xD;
                    -  No unrelated healthy participant with 2 or more of the following features:&#xD;
&#xD;
                         -  History of ovarian or cardiac fibroma&#xD;
&#xD;
                         -  Mesenteric or pleural cysts&#xD;
&#xD;
                         -  Polydactyly&#xD;
&#xD;
                         -  Macrocephaly determined after adjustment for height&#xD;
&#xD;
                         -  Craniofacial features of BCNS, including cleft palate, frontal bossing,&#xD;
                            hypertelorism, iris coloboma or other developmental defects of the eye,&#xD;
                            or coarse facies&#xD;
&#xD;
                         -  Vertebral anomalies, including spina bifida occulta outside the lumbar&#xD;
                            region&#xD;
&#xD;
                         -  Bifid or splayed ribs&#xD;
&#xD;
                         -  Other radiographic findings, including bridging of the sella turcica,&#xD;
                            nonlamellar calcification of the falx cerebri, or flame-shaped&#xD;
                            lucencies in the phalanges = 1-3 BCCs over the age of 30&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WBC ≥ 4,000/mm³&#xD;
&#xD;
          -  Neutrophil count ≥ 2,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 150,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 11.5 g/dL&#xD;
&#xD;
          -  Bilirubin 0.3-1.0 mg/dL&#xD;
&#xD;
          -  AST 17-59 U/L&#xD;
&#xD;
          -  PTT 10-13 seconds OR INR 1.0-1.4&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  Cholesterol &lt; 350 mg/dL&#xD;
&#xD;
          -  Triglycerides &lt; 400 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile participants must use effective contraception for ≥ 1 month before, during,&#xD;
             and for ≥ 12 weeks after study treatment&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No alcohol or drug abuse&#xD;
&#xD;
          -  No psychiatric disorder or mental deficiency that would preclude study compliance&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., blood pressure &gt; 140/90 mm Hg on &gt; 2 measurements)&#xD;
&#xD;
          -  No chronic active infection requiring treatment&#xD;
&#xD;
          -  No untreated reactive purified protein derivative of tuberculin (PPD)&#xD;
&#xD;
          -  No HIV-1 infection&#xD;
&#xD;
          -  No infection requiring antibiotics within the past 30 days&#xD;
&#xD;
          -  No other skin disease affecting broad areas of the body, including the region to be&#xD;
             treated and biopsied&#xD;
&#xD;
          -  No known hepatitis B or C infection (detectable RNA off antiviral therapy)&#xD;
&#xD;
          -  No immune deficiency disorder&#xD;
&#xD;
          -  No known hypersensitivity to sirolimus or macrolide antibiotics (e.g., erythromycin,&#xD;
             azithromycin, or clarithromycin)&#xD;
&#xD;
          -  No cancer within the past 5 years except basal cell skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 1 month since prior investigational drugs&#xD;
&#xD;
          -  No concurrent dietary supplements, including Hypericum perforatum (St. John's wort) or&#xD;
             megadose vitamins&#xD;
&#xD;
          -  No other concurrent immunosuppressive medications, including corticosteroids&#xD;
&#xD;
          -  No concurrent medications known to interfere with sirolimus metabolism&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
&#xD;
          -  No concurrent acetylsalicyclic acid or other drugs affecting platelet function or&#xD;
             number&#xD;
&#xD;
          -  No routine (i.e., &gt; 2 doses/week) use of nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  No drugs or substances that would effect sirolimus blood concentrations, including any&#xD;
             of the following:&#xD;
&#xD;
               -  Nicardipine&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Clotrimazole&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Troleandomycin&#xD;
&#xD;
               -  Cisapride&#xD;
&#xD;
               -  Metoclopramide&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Bromocriptine&#xD;
&#xD;
               -  Cimetidine&#xD;
&#xD;
               -  Danazol&#xD;
&#xD;
               -  HIV-protease inhibitors (e.g., ritonavir or indinavir)&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Rifapentine&#xD;
&#xD;
               -  Grapefruit juice&#xD;
&#xD;
               -  Vaccinations (especially live vaccines)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen E. Bale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>basal cell carcinoma of the skin</keyword>
  <keyword>nevoid basal cell carcinoma syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Basal Cell Nevus Syndrome</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

